Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer

Journal of Clinical Oncology

Volumn 15, Issue 1, 1997, Pages 261-267

  Webb, A ^a   Cunningham, D ^a   Scarffe, J H ^a   Harper, P ^a   Norman, A ^a   Joffe, J K ^a   Hughes, M ^a   Mansi, J ^a   Findlay, M ^a   Hill, A ^a   Oates, J ^a   Nicolson, M ^a   Hickish, T ^a   O'Brien, M ^a   Iveson, T ^a   Watson, M ^a   Underhill, C ^a   Wardley, A ^a   Meehan, M ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; ESOPHAGUS CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0031022803     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.1.261     Document Type: Article

References (35)

1. Thompson GB, Van Heerden JA: Adenocarcinoma of the stomach: Are we making any progress? Lancet 342:713-718, 1993
2. Akoh AJ, McIntyre IMC: Improving survival in gastric cancer: Review of 5-year survival rates in English language publications from 1970. Br J Surg 79:293-299, 1992
3. Pyrhönen S, Kuitunen T, Kouri M: A randomized phase III trial comparing fluorouracil, epidoxorubicin and methotrexate (FEMTX) with best supportive care in non-resectablc gastric cancer. Ann Oncol 3:12, 1992 (suppl 5, abstr 47)
4. Murad A, Santiago FF, Petroianou A, et al: Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 72:37-41, 1993
5. Wils O, Klein HO, Wagener DJT, et al: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: A step ahead in the treatment of gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Co-operative Group. J Clin Oncol 9:827-831, 1991
6. Preusser P, Wilke H, Achterrath W, et al: Phase II study with the combination etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7:1310-1317, 1989
7. Kelsen D, Atiq OT, Saltz L, et al: FAMTX versus etoposide, doxorubicin and cisplatin: A randomized trial in gastric cancer. J Clin Oncol 10:541-548, 1992
8. Wilke H, Wils J, Rougier P, et al: Preliminary analysis of a randomized phase III trial of FAMTX versus ELF versus cisplatin/FU in advanced gastric cancer. A trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group and the AIO (Arbeitsge-Meinschaft Internistische Onkologie). Proc Am Soc Clin Oncol 14:206, 1995 (abstr)
9. Cunningham D, Mansi J, Ford HT, et al: Epirubicin, cisplatin and 5-fluorouracil (ECF) is highly effective in advanced gastric-cancer. Proc Am Soc Clin Oncol 10:136, 1991 (abstr 412)
10. MacDonald JS: Gastric cancer: Chemotherapy of advanced disease. Haematol Oncol 10:37-42, 1992
11. Machover D, Goldschmidt E, Chollet P, et al: Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high dose folinic acid. J Clin Oncol 4:685-696, 1986
12. Beer M, Cocconi G, Ceci G, et al: A phase II study of cisplatin in advanced gastric cancer. Eur J Cancer Clin Oncol 19:717-720, 1983
13. Cersosimo RJ, Hong WK: Epirubicin: A review of the pharmacology and adverse effects of an Adriamycin analogue. J Clin Oncol 4:425-434, 1986
14. Etienne MC, Bernard S, Fischel JL, et al: Dose reduction without loss of efficacy of 5-fluorouracil and cisplatin combined with folinic acid: In vitro studies on human head and neck carcinoma cell lines. Br J Cancer 63:372-377, 1991
15. Brambilla C, Rossi A, Bonfante V, et al: Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep 70):261-266, 1986
16. Kyoto Research Group for Chemotherapy of Gastric Cancer: Randomized, comparative study of combination chemotherapy in advanced gastric cancer: 5-Fluorouracil and cisplatin (FP) versus 5-fluorouracil, cisplatin and 4′-epirubicin (FPEPIR). Anticancer Res 12:1983-1988, 1992
17. Lokich JJ, Ahlgren JD, Gullo JJ, et al: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A MidAtlantic Oncology Program study. J Clin Oncol 7:425-432, 1989
18. Findlay M, Cunningham D, Norman A, et al: A phase II study in advanced gastric cancer using epirubicin and cisplatin in combination with continuous 5-FU (ECF). Ann Oncol 5:609-616, 1994
19. Jones AL, Smith IE, O'Brien MER, et al: Phase II study of continuous infusion 5-FU with epirubicin and cisplatin (infusional ECF) in patients with metastatic and locally advanced breast cancer: An active new regimen. J Clin Oncol 12:1259-1265, 1994
20. Smith IE, Walsh G, Jones A, et al: High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 13:424-429, 1995
21. National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988
22. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
23. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in the international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
24. Ringdal GI, Ringdal K: Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses. Qual Life Res 2:129-140, 1993
25. Hjermsted MJ, Fossa SD, Bjordal K, et al: Test/retest study of the European Organization for Research and Treatment of Cancer Care Quality-of-Life Questionnaire. 13:1249-1254, 1995
26. Drummond MF, Stoddart GL, Torrance GW: Methods for the Economic Evaluation of Health Care Programmes. New York, NY, Oxford University, 1987
27. Glimelius B, Hoffman K, Graf W, et al: Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 6:267-274, 1995
28. Bern MM, Lokich JJ, Wallach SR, et al: Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 112:423-428, 1990
29. Anderson N, Lokich J: Controversial issues in 5-fluorouracil infusion use. Dose intensity, treatment duration, and cost comparisons. Cancer 70:998-1002, 1992 (suppl 4)
30. Kaplan RM, Bush JW: Health related quality of life measurement for evaluation research and policy analysis. Health Psychol 1:61-80, 1982
31. Eldelson JT, Weinstein MC, Tosteson AN, et al: Long term cost effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 263:407-413, 1990
32. Weinstein MC, Stason WB: Cost effectiveness of coronary artery bypass surgery. Circulation 66:56-65, 1982 (suppl 3)
33. Fraile RJ, Baker LH, Buroker TR, et al: Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 40:2223-2228, 1980
34. Lokich J, Bothe A, Fine N, et al: Phase I study of protracted venous infusion of 5-fluorouracil. Cancer 48:2565-2568, 1981
35. Scanlon KJ, Newman EM, Lu Y, et al: Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83:8923-8925, 1986